Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/11/2019 |
Start Date: | April 2012 |
End Date: | November 2023 |
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast
cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs
in different combinations may kill more breast cancer cells. Giving combination chemotherapy
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy
regimens and their side effects and comparing how well they work in treating women with
non-metastatic breast cancer.
cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs
in different combinations may kill more breast cancer cells. Giving combination chemotherapy
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy
regimens and their side effects and comparing how well they work in treating women with
non-metastatic breast cancer.
OBJECTIVES:
Primary
- To determine if the docetaxel and cyclophosphamide (TC) regimen is non-inferior to the
anthracycline-based chemotherapy regimens in terms of invasive disease-free survival
(DFS) by combining B-49 data with the docetaxel, doxorubicin, and cyclophosphamide (TAC)
and TC arms of NSABP B-46-I/US Oncology Research, Inc.(USOR) 07132 and the data from
USOR 06-090.
Secondary
- To determine rates of DFS-ductal carcinoma in situ (DCIS) for the TC and
anthracycline-based chemotherapy regimens.
- To determine rates of overall survival (OS) for the TC and anthracycline-based
chemotherapy regimens.
- To determine rates of recurrence-free interval (RFI) for the TC and anthracycline-based
chemotherapy regimens.
- To evaluate the toxicity associated with each of the regimens.
- To determine the role of TOP2A in prognosis and prediction of degree of benefit from
anthracycline-based chemotherapy over TC. (exploratory)
- To develop predictive markers for benefit from doxorubicin. (exploratory)
OUTLINE: This is a multicenter randomized study. Patients are stratified according to number
of positive nodes (0 vs 1-3 vs 4-9 vs 10+) and hormone-receptor status (estrogen receptor
[ER] and/or progesterone receptor [PgR] positive vs ER and PgR negative). Patients are
randomized to 1 of 2 treatment arms.
Primary
- To determine if the docetaxel and cyclophosphamide (TC) regimen is non-inferior to the
anthracycline-based chemotherapy regimens in terms of invasive disease-free survival
(DFS) by combining B-49 data with the docetaxel, doxorubicin, and cyclophosphamide (TAC)
and TC arms of NSABP B-46-I/US Oncology Research, Inc.(USOR) 07132 and the data from
USOR 06-090.
Secondary
- To determine rates of DFS-ductal carcinoma in situ (DCIS) for the TC and
anthracycline-based chemotherapy regimens.
- To determine rates of overall survival (OS) for the TC and anthracycline-based
chemotherapy regimens.
- To determine rates of recurrence-free interval (RFI) for the TC and anthracycline-based
chemotherapy regimens.
- To evaluate the toxicity associated with each of the regimens.
- To determine the role of TOP2A in prognosis and prediction of degree of benefit from
anthracycline-based chemotherapy over TC. (exploratory)
- To develop predictive markers for benefit from doxorubicin. (exploratory)
OUTLINE: This is a multicenter randomized study. Patients are stratified according to number
of positive nodes (0 vs 1-3 vs 4-9 vs 10+) and hormone-receptor status (estrogen receptor
[ER] and/or progesterone receptor [PgR] positive vs ER and PgR negative). Patients are
randomized to 1 of 2 treatment arms.
Inclusion Criteria:
- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1.
- The tumor must be unilateral invasive adenocarcinoma of the breast on histologic
examination.
- The breast cancer must be Human Epidermal Growth Factor Receptor 2 (HER2)-negative
based on current American Society of Clinical Oncology (ASCO)/CAP Guideline
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
If the result of the in situ hybridization testing (FISH, chromagen in situ
hybridization [CISH], or other) is equivocal, the patient is eligible if there is no
plan to administer HER2-targeted therapy.
- All of the following staging criteria must be met according to American Joint
Committee on Cancer (AJCC) criteria:
- By pathologic evaluation, primary tumor must be pT1-3;
- By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b,
pN1c), pN2a, pN3a, or pN3b.
- If pN0, at least one of the following criteria must be met:
- ER negative and PgR negative; or
- Pathologic tumor size greater than 2.0 cm; or
- T1c (pathologic tumor size greater than 1.0 cm but less than or equal to 2.0 cm)
and ER positive (PgR status may be positive or negative) and either grade 3
histology or Oncotype DX® Recurrence Score of greater than or equal to 25.
- Patients must have undergone either a total mastectomy or breast-conserving surgery
(lumpectomy).
- For patients who undergo lumpectomy, the margins of the resected specimen must be
histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as
determined by the local pathologist. If pathologic examination demonstrates tumor at
the line of resection, additional operative procedures must be performed to obtain
clear margins. If tumor is still present at the resected margin after re-excision(s),
the patient must undergo total mastectomy to be eligible. (Patients with margins
positive for lobular carcinoma in situ [LCIS] are eligible without additional
resection.)
- For patients who undergo mastectomy, margins must be histologically free of invasive
tumor and DCIS.
- Patients must have completed one of the following procedures for evaluation of
pathologic nodal status:
- Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel
lymphadenectomy is pN0, pN1mi, or pN1b;
- Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel
lymphadenectomy is pN1a limited to 1 or 2 positive nodes and primary tumor is T1
or T2 by pathologic evaluation;
- Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph
nodes if the sentinel node (SN) is positive; or
- Axillary lymphadenectomy with or without SN isolation procedure.
- The interval between the last surgery for breast cancer (treatment or staging) and
randomization must be no more than 84 days.
- Patients must have ER analysis performed on the primary tumor prior to randomization.
Breast cancer must be assessed for ER status by current ASCO/CAP Guideline
Recommendations for hormone receptor testing. If negative for ER, assessment of PgR
must also be performed according to current ASCO/CAP Guideline Recommendations for
hormone receptor testing. (Either a core biopsy or surgical resection specimen can be
used for ER/PgR testing.)
- The most recent postoperative blood counts, performed within 6 weeks prior to
randomization, must meet the following criteria:
- absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3;
- platelet count must be greater than or equal to 100,000/mm3; and
- hemoglobin must be greater than or equal to 10 g/dL.
- The following criteria for evidence of adequate hepatic function must be met based on
the results of the most recent postoperative tests performed within 6 weeks prior to
randomization:
- total bilirubin must be less than or equal to upper limit of normal (ULN) for the
lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN
due to Gilbert's disease or similar syndrome involving slow conjugation of
bilirubin; and
- alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and
- aspartate transaminase (AST) must be less than or equal to 1.5 x ULN for the lab.
- Alkaline phosphatase and AST may not both be greater than the ULN. For example,
if the alkaline phosphatase is greater than the ULN but less than or equal to 2.5
x ULN, then the AST must be less than or equal to the ULN. If the AST is greater
than the ULN but less than or equal to 1.5 x ULN, then the alkaline phosphatase
must be less than or equal to ULN.
- Note: If alanine aminotransferase (ALT) is performed instead of AST (per
institution's standard practice), the ALT value must be less than or equal to 1.5
x ULN; if both were performed, the AST must be less than or equal to 1.5 x ULN.
- Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion
in the study if liver imaging (CT, MRI, PET-CT, or PET scan performed within 90 days
prior to randomization) does not demonstrate metastatic disease and the requirements
for adequate hepatic function as described above are met.
- Patients with alkaline phosphatase that is greater than ULN but less than or equal to
2.5 x ULN are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET
scan performed within 90 days prior to randomization does not demonstrate metastatic
disease.
- The most recent postoperative serum creatinine performed within 6 weeks prior to
randomization must be less than or equal to ULN for the lab.
- Left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or
multigated acquisition (MUGA) scan must be performed within 90 days prior to
randomization. The LVEF must be greater than or equal to 50% regardless of the
facility's lower limit of normal (LLN). (If the facility performing the assessment has
not reported the LVEF as a whole number, decimals reported as greater than or equal to
5 should be rounded up and decimals reported as less than 5 should be rounded down.)
Exclusion criteria:
Patients with one or more of the following conditions are ineligible for this study.
- T4 tumors including inflammatory breast cancer.
- Definitive clinical or radiologic evidence of metastatic disease. (Chest imaging
[mandatory for all patients] and other imaging [if required] must have been performed
within 90 days prior to randomization.)
- Synchronous or previous contralateral invasive breast cancer. (Patients with
synchronous and/or previous contralateral DCIS are eligible.)
- Any history of ipsilateral invasive breast cancer or ipsilateral DCIS.
- History of non-breast malignancies within 5 years prior to randomization, except for
the following: carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma
in situ, and basal cell and squamous cell carcinomas of the skin.
- Previous therapy with anthracyclines or taxanes for any malignancy.
- Chemotherapy administered for the currently diagnosed breast cancer prior to
randomization.
- Continued endocrine therapy such as raloxifene or tamoxifen (or other SERM) or an
aromatase inhibitor. Patients are eligible if these medications are discontinued prior
to randomization.
- Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement
therapy. Patients are eligible if these medications are discontinued prior to
randomization.
- Known active hepatitis B or hepatitis C with abnormal liver function tests.
- Cardiac disease (history of and/or active disease) that would preclude the use of the
drugs included in the treatment regimens. This includes but is not confined to:
- Active cardiac disease
- angina pectoris that requires the use of anti-anginal medication;
- ventricular arrhythmias except for benign premature ventricular contractions;
- supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
with medication;
- conduction abnormality requiring a pacemaker;
- valvular disease with documented compromise in cardiac function;
- symptomatic pericarditis.
- History of cardiac disease
- myocardial infarction documented by elevated cardiac enzymes or persistent
regional wall abnormalities on assessment of left ventricular function;
- history of documented congestive heart failure (CHF);
- documented cardiomyopathy.
- Whole breast radiation therapy (RT) prior to randomization or partial breast RT that
cannot be completed on or before the date of randomization.
- Intrinsic lung disease resulting in dyspnea.
- Unstable diabetes mellitus.
- Active infection or chronic infection requiring suppressive antibiotics.
- History of a major organ allograft or condition requiring chronic immunosuppression,
e.g., kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases.
(Patients who have received corneal transplants, cadaver skin, or bone transplants are
eligible.)
- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) greater than or equal to grade 2, per the NCI CTCAE v4.0.
- Conditions that would prohibit administration of corticosteroids.
- Chronic daily treatment with corticosteroids (dose of greater than or equal to 10
mg/day methylprednisolone equivalent) (excluding inhaled steroids).
- History of hypersensitivity reaction to drugs formulated with polysorbate 80.
- Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be
performed within 2 weeks prior to randomization according to institutional standards
for women of childbearing potential.)
- Other non-malignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow-up.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements.
- Use of any investigational product within 30 days prior to randomization.
We found this trial at
916
sites
Click here to add this to my saved trials
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Click here to add this to my saved trials
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
3 Butternut Drive, Suite B
Greenville, South Carolina 29605
Greenville, South Carolina 29605
(864) 241-7272
Cancer Centers of the Carolinas - Grove Commons Cancer Centers of the Carolinas is now...
Click here to add this to my saved trials
340 Medical Pkwy
Greer, South Carolina 29650
Greer, South Carolina 29650
(864) 334-4900
Cancer Centers of the Carolinas - Greer Medical Oncology Cancer Centers of the Carolinas is...
Click here to add this to my saved trials
Univ of Hawaii Honolulu Community College is an integral part of the University of Hawai?i,...
Click here to add this to my saved trials
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Naval Medical Center - San Diego We are the largest and most comprehensive military healthcare...
Click here to add this to my saved trials
100 Campus Dr # 108
Scarborough, Maine 04074
Scarborough, Maine 04074
(207) 396-7600
Maine Center for Cancer Medicine and Blood Disorders - Scarborough Maine Center for Cancer Medicine...
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
206-667-4584
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
Click here to add this to my saved trials
131 Lila Doyle Drive
Seneca, South Carolina 29672
Seneca, South Carolina 29672
(864) 888-3717
Cancer Centers of the Carolinas - Seneca Cancer Centers of the Carolinas is now Cancer...
Click here to add this to my saved trials
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
120 Dillon Dr
Spartanburg, South Carolina 29307
Spartanburg, South Carolina 29307
(864) 699-5700
Cancer Centers of the Carolinas - Spartanburg Cancer Centers of the Carolinas is now Cancer...
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
Click here to add this to my saved trials
Wenatchee Valley Medical Center Established on July 21, 2013, Confluence Health is an affiliation between...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Akron General Medical Center It
Click here to add this to my saved trials
Summa Akron City Hospital Summa Akron City Hospital was founded in 1892 to provide a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Lehigh Valley Hospital At Lehigh Valley Health Network, we continually go the extra mile to...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
Michigan Cancer Research Consortium Community Clinical Oncology Program The Community Clinical Oncology Program (CCOP) is...
Click here to add this to my saved trials
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
Click here to add this to my saved trials
Mission Hospitals Mission Hospital, the flagship hospital of Mission Health, has been committed to improving...
Click here to add this to my saved trials
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Click here to add this to my saved trials
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials